Journal article
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
- Abstract:
-
Tumour hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clinical outcomes. To find clinical candidate compounds that reduce hypoxia in tumours, we conduct a high-throughput screen for oxygen consumption rate (OCR) reduction and identify a number of drugs with this property. For this study we focus on the anti-malarial, atovaquone. Atovaquone rapidly decreases the OCR by more than 80% in a wide range of cancer cell lines at pharmacological concentrations. I...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bibliographic Details
- Publisher:
- Nature Publishing Group: Nature Communications Publisher's website
- Journal:
- Nature communications Journal website
- Volume:
- 7
- Pages:
- 12308
- Publication date:
- 2016-07-25
- Acceptance date:
- 2016-06-17
- DOI:
- ISSN:
-
2041-1723
- Pmid:
-
27453292
Item Description
- Language:
- English
- Subjects:
- Pubs id:
-
pubs:636321
- UUID:
-
uuid:15d89091-2bfd-4609-80fa-c5157ea5d1c9
- Local pid:
- pubs:636321
- Source identifiers:
-
636321
- Deposit date:
- 2017-10-19
Terms of use
- Copyright holder:
- Ashton et al
- Copyright date:
- 2016
- Notes:
- Copyright The Author(s) 2016. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record